Table 2. Recommended Treatment Regimens for Anogenital Warts Based on Anatomic Location

<table>
<thead>
<tr>
<th>Anatomic location</th>
<th>Patient-applied</th>
<th>Provider-administered</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Podoflox&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Imiquimod&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>External genital</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Meatus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vagina</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical/rectal</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Anal/peri-anal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: TCA/BCA, trichloroacetic acid or bichloroacetic acid 90%–90%.
<sup>a</sup> Adapted from the 2010 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.
<sup>b</sup> Podoflox, podophyllin, imiquimod, and sinecatechins are not recommended during pregnancy.
<sup>c</sup> Alternative regimens include intralesional interferon, laser therapy, topical cidocidovir, and other.
<sup>d</sup> Some experts recommend use of podoflox or imiquimod, but limited data exist.

with patients; however, recommendations for condom use may not be realistic or palatable for some patients, particularly those in long-term, monogamous relationships.

Because of the possible distress associated with HPV diagnoses and the large number of HPV-associated visits at STD clinics, we have included messages to guide patient education and counseling. The messages address common questions encountered by providers and include messages for persons with genital warts and their partners, women undergoing cervical cancer screening, and women who have an abnormal Pap test and/or HR HPV test result and their partners. General HPV information is also provided below, which should accompany the key messages for specific patient scenarios.

Notes

Acknowledgments. We thank the many contributors to the review on HPV and genital warts for the CDC STD Treatment Guidelines. The following experts spent dedicated time to the review and revision of information included in this document: Kevin Ault, John T. Brooks, John Douglas, Kenneth H. Fife, Alex Ferenczy, Suzanne Garland, Laura Koutsky, Anna-Barbara Moscicki, Joel Palefsky, Kees Rietmeijer, Mona Sariya, Katherine Stone, Elizabeth Unger, Dorothy Wiley, and Fred Wyand.

Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agency.

Supplement sponsorship. This article was published as part of a supplement entitled "Sexually Transmitted Disease Treatment Guidelines" sponsored by the Centers for Disease Control and Prevention.

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

17. Food and Drug Administration. Product approval information—licensing action, package insert: Gardasil (quadrivalent human papillomavirus types


New HPV Vaccine Recommendations • CID 2011;53 (Suppl 3) • S149


